ArticleJournal of fungi (Basel, Switzerland)2020
Isavuconazole Treatment in a Mixed Patient Cohort with Invasive Fungal Infections: Outcome, Tolerability and Clinical Implications of Isavuconazole Plasma Concentrations.
Article in Journal of fungi (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Guideline
- Population pharmacokinetics, target attainment and individualized dosing of isavuconazole in critically ill adults receiving extracorporeal membrane oxygenation.JAC-antimicrobial resistance · 2026Article
- Antibiotics and Other Drugs Removal by the CytoSorbAntibiotics (Basel, Switzerland) · 2026Review
- Liver Necrosis in a Patient Receiving Isavuconazole: Making the Case for Therapeutic Drug Monitoring.Open forum infectious diseases · 2026Article
- Isavuconazole in Pediatric Invasive Fungal Infections: Outcomes and Therapeutic Drug Monitoring in a Chinese Multicenter Case Series.Infection and drug resistance · 2026Article
- Use of isavuconazole in critically ill patients in intensive care units: a prospective, observational, multicentre, cohort study.JAC-antimicrobial resistance · 2025Article
- Antimicrobial dosing considerations in critically ill patients with acute kidney injury: A review.World journal of nephrology · 2025Review
- Low isavuconazole trough levels in critically ill patients with and without extracorporeal membrane oxygenation.Antimicrobial agents and chemotherapy · 2025Article
- Pharmacokinetic study of isavuconazonium in human plasma measured by HPLC-MS/MS and its use in healthy Chinese subjects.Bioanalysis · 2025Article
- Optimization of Isavuconazole Dosing in Patients with Invasive Fungal Infections Through Therapeutic Drug Monitoring: Real-World Clinical Practice Experience.Life (Basel, Switzerland) · 2025Article
- Pharmacokinetics of Isavuconazole During Extracorporeal Membrane Oxygenation Support in Critically Ill Patients: A Case Series.Antibiotics (Basel, Switzerland) · 2025Article
- Managing Invasive Fungal Infections During Allogeneic Hematopoietic Transplantation: A 2025 Update.Mediterranean journal of hematology and infectious diseases · 2025Review
- Navigating Therapeutic drug monitoring of Isavuconazole in Invasive Mold Infection on Extracorporeal membrane oxygenation - A Case Report.Innovations in pharmacy · 2025Article
- Navigating Uncertainty: Managing Influenza-Associated Invasive Pulmonary Aspergillosis in an Intensive Care Unit.Journal of fungi (Basel, Switzerland) · 2024Article
- Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.Antibiotics (Basel, Switzerland) · 2024Article
- [Pharmacokinetic monitoring of isavuconazole in a patient with extracorporeal membrane oxygenation support].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2024Article
- COVID-19-associated pulmonary aspergillosis in intensive care unit: A real-life experience.Heliyon · 2024Article
- Isavuconazole use and TDM in real-world pediatric practice.Antimicrobial agents and chemotherapy · 2023Article
- Treatment of Invasive Aspergillosis: How It's Going, Where It's Heading.Mycopathologia · 2023Review
- Real-World, Multicenter Case Series of Patients Treated with Isavuconazole for Invasive Fungal Disease in China.Microorganisms · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 3 countries.
Funding
Abstract
Isavuconazole (ISA) is a triazole antifungal agent recommended for treatment of invasive aspergillosis or mucormycosis. The objective of this study was to evaluate ISA levels in a real world setting in a mixed patient cohort including patients with non-malignant diseases and extracorporeal treatments, and to correlate findings with efficacy and safety outcomes. We investigated 33 ISA treatment courses in 32 adult patients with hematological and other underlying diseases and assessed the clinical response, side effects and ISA trough plasma concentrations. ISA treatment led to complete and partial response in 87% of patients and was well tolerated. The median ISA plasma concentration was 3.05 µg/mL (range 1.38-9.1, IQR 1.93-4.35) in patients without renal replacement therapy (RRT) or extracorporeal membrane oxygenation (ECMO) and significantly lower in patients with RRT including cases with additional ECMO or Cytosorb
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.